Captor Therapeutics stock reports a PLN 22.76 million H1 loss

Captor Therapeutics stock was trading at PLN 70.00 on the Warsaw Stock Exchange on September 24, 2026, down 0.43 percent from the previous close. The Polish biotechnology company reported a PLN 22.76 million net loss for the first half of 2026, compared with PLN 20.47 million a year earlier.

H1 loss widens on lower revenue

MarketScreener reported on September 15, 2026, that Captor Therapeutics posted a PLN 22.76 million net loss for the six months ended June 30, 2026, against PLN 20.47 million in the prior-year period. Basic loss per share was PLN 3.86, compared with PLN 3.72 previously.

Revenue from research and development services fell to PLN 1.962 million in H1 2026 from PLN 4.616 million in H1 2025. The comparison points to lower collaboration activity, while research and project costs continued to weigh on earnings.

Cash runway reaches Q3 2027

Cash and investments stood at PLN 71.5 million at the end of June 2026. According to Bankier on September 18, 2026, company representatives said those resources should support operations through at least the third quarter of 2027, while the company maintained its goal of signing a partnering agreement in 2026.

The funding position changes the near-term reading of the loss. Captor can continue clinical and preclinical work while pursuing partnerships, but the H1 figures show that operating progress remains tied to collaboration income and capital discipline.

Stock trades below yearly high

Captor Therapeutics had a market capitalization of PLN 443,337,790 on September 24, 2026. Its 52-week range was PLN 35.10 to PLN 89.20, placing the PLN 70.00 price 21.5 percent below the yearly high and 99.4 percent above the yearly low.

Price holds at PLN 70

The intraday quote was PLN 70.00 on the Warsaw Stock Exchange at 9:03 a.m. CEST on September 24, 2026, with a daily change of minus 0.43 percent. The combination of a cash runway through Q3 2027 and a wider H1 loss leaves partnership execution and clinical progress as the key company-specific variables.